ReviewInfection and drug resistance2015
New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid.
Review in Infection and drug resistance, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Efficacy and safety data on pretomanid for drug-resistant TB.IJTLD open · 2025Review
- Nuclear Magnetic Resonance Fingerprinting and Principal Component Analysis Strategies Lead to Anti-Tuberculosis Natural Product Discovery from Actinomycetes.Antibiotics (Basel, Switzerland) · 2025Article
- Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens.PLOS global public health · 2025Article
- The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran.Annals of clinical microbiology and antimicrobials · 2024Article
- Synthesis, Characterization, and Stability Assessment for the Benzoate, Hydrochloride, Malonate, and Nicotinate Salts of Bedaquiline.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Characterization of Clofazimine Metabolism in Human Liver Microsomal IncubationAntimicrobial agents and chemotherapy · 2022Article
- Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?Children (Basel, Switzerland) · 2022Review
- Delamanid suppresses CXCL10 expressionFrontiers in immunology · 2022Article
- Article
- Maleate salts of bedaquiline.Acta crystallographica. Section E, Crystallographic communications · 2021Article
- Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin.The South African journal of communication disorders = Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings · 2021Article
- Crystal structures of salts of bedaquiline.Acta crystallographica. Section C, Structural chemistry · 2020Article
- Cinnamic Derivatives as Antitubercular Agents: Characterization by Quantitative Structure-Activity Relationship Studies.Molecules (Basel, Switzerland) · 2020Article
- Antimycobacterial and PknB Inhibitory Activities of Venezuelan Medicinal Plants.International journal of microbiology · 2020Article
- Article
- Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis.Southern African journal of infectious diseases · 2020Article
- Article
- Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.Antimicrobial agents and chemotherapy · 2018Article
- Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy.The Journal of antimicrobial chemotherapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment for drug-resistant tuberculosis (TB) is long, complex, and associated with severe and life-threatening side effects and poor outcomes. For the first time in nearly 50 years, there have been two new drugs registered for use in multidrug-resistant TB (MDR-TB). Bedaquiline, a diarylquinoline, and delamanid, a nitromidoxazole, have received conditional stringent regulatory approval and have World Health Organization interim policy guidance for their use. As countries improve and scale up their diagnostic services, increasing number of patients with MDR-TB and extensively drug-resistant TB are identified. These two new drugs offer a real opportunity to improve the outcomes of these patients. This article reviews the evidence for these two new drugs and discusses the clinical questions raised as they are used outside clinical trial settings. It also reviews the importance of the accompanying drugs used with these new drugs. It is important that barriers hindering the use of these two new drugs are addressed and that the existing clinical experience in using these drugs is shared, such that their routine-use programmatic conditions is scaled up, ensuring maximum benefit for patients and countries battling the MDR-TB crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.